Next-generation cell and gene therapies are spurring demand for manufacturing space in key life sciences clusters
Life sciences is a sector with longstanding clustering tendencies! Indeed, the benefits of physical proximity, collaboration and knowledge-sharing are widely recognised, both for collections of companies and constituent parts of the same organisation.
In a recent EY study, life sciences executives attributed 14.6% of revenues and 13.7% of cost savings to an ecosystem involvement. EY also reported that the companies with the highest performing ecosystems added a further 1.7 times more to annual revenue and two times the incremental revenue growth.
And there are other ways of measuring the benefits. AstraZeneca recognised the R&D potential of locating in the Cambridge ecosystem. Collaboration with some of the world’s best scientists was at the heart of …
More on: www.pharmatimes.com